Dataset Information

Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring

ABSTRACT: Colorectal cancer (CRC) is currently the third leading cause of cancer related mortality in the world. U.S. Food and Drug Administration-approval circulating tumor markers, including carcinoembryonic antigen, carbohydrate antigen (CA) 19-9 and CA125, were used as prognostic biomarker of CRC that attributed to low sensitivity in diagnosis of CRC. Therefore, our purpose is to develop a novel strategy for novel clinical biomarker for early CRC diagnosis. We used mass spectrometry (MS) methods such as nanoLC-MS/MS, targeted LC-MS/MS, and stable iso-tope-labeled multiple reaction monitoring (MRM) MS coupled to machine learning algorithms and logistic regression to analyze plasma samples from patients with early-stage CRC, late-stage CRC, and healthy controls (HCs).

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Colon Cancer

SUBMITTER: I Jung Tsai

LAB HEAD: Ching-Yu Lin

PROVIDER: PXD024997 | Pride | 2021-07-29

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Differentially_expressed_peptides_.xlsx	Xlsx
	Discovery_HC_1.raw	Raw
	Discovery_HC_2.raw	Raw
	Discovery_Pooling-1.raw	Raw
	Discovery_Pooling-2.raw	Raw

Items per page:

1 - 5 of 15

Similar Datasets

Project description:Colorectal cancer (CRC) is one of the major causes of cancer-related death worldwide, for which diagnosis and prognosis are still inadequate mainly due to local recurrence and metastasis, although medical and surgical treatment in cancer therapy advanced. Diagnosis is frequently late, the high capacity of CRC to infiltrate and develop metastasis has the consequence that 40% of patients with CRC have metastasis in liver already at the time of diagnosis. The prognosis of CRC is closely related to the stage, but classification of patients is affected by a great variability in response to therapy and clinical outcome. The localization of the tumor determines a huge inter-tumoral heterogeneity and the intra-tumoral heterogeneity connected to the tumor microenvironment increases the complexity. The heterogeneity typical of CRC is also associated to the several oncogenic signaling pathways, among them the glucose-related pathways, indeed, the glucose metabolic reprogramming of cancer cells appears to be implicated in the malignant progression of CRC. This metabolic alteration seems to be associated to the epithelial-mesenchymal transition (EMT), which is considered the main event promoting the invasion and migration of CRC cells. However, the comprehensive understanding of the molecular mechanisms associated to EMT in CRC is still a challenge and despite decades of research, the process of tumor dissemination is insufficiently understood. Therefore, it is necessary to identify novel biomarkers associated with the prevention, diagnosis and treatment of CRC, as well as potential therapeutic targets. In this context, we performed a large-scale shotgun proteomic investigation on CRC with the aim of discover novel potential protein hallmarks able to distinguish with high specificity and sensitivity tumoral tissue from the health one, and to classify the superficial and the internal deep tumoral tissues. The EMT process is driven by the deep tumoral cells in CRC, therefore, to find significant differences at proteomic levels with respect to the peripheric tumoral tissue and to the healthy mucosa, and to identify specific classifying factors can be useful to individuate potential biomarkers of CRC invasiveness and potential therapy targets. Moreover, the functional enrichment analysis of proteomic data can provide information on biological processes implicated and associated to the variations of the protein profiles, and thus, help to understand the molecular mechanism associated to the CRC progression and malignance. Our approaches coupling high-throughput proteomic strategy with highly accurate statistical and enrichments analysis highlighted not only confirmation on potential biomarkers already proposed in other studies but also novel biomarkers able to distinguish with high sensitivity and specificity the deep tumor from the superficial one and to the healthy mucosa. Our investigation suggested a strong contribution of proteins implicated in metabolic pathways as catalytic and regulatory activities, some of them with high classifying power and potentially useful as biomarker and therapeutic target.

Dataset Information

Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets